Head and neck squamous cell carcinomas

Recommendations from the society for diagnosis and therapy of haematological and oncological diseases
The information of the DGHO Onkopedia Web Site is not intended or implied to be a substitute for professional medical advice or medical care. The advice of a medical professional should always be sought prior to commencing any form of medical treatment. To this end, all component information contained within the web site is done so for solely educational purposes. DGHO Deutsche Gesellschaft für Hämatologie und Onkologie and all of its staff, agents and members disclaim any and all warranties and representations with regards to the information contained on the DGHO Web Site. This includes any implied warranties and conditions that may be derived from the aforementioned web site information.
# Table of contents

1 Summary ........................................................................................................... 3

2 Basics ................................................................................................................ 3

2.1 Definition and basic information .................................................................. 3

2.2 Epidemiology (Figures 1-4) ......................................................................... 3

2.3 Pathogenesis .................................................................................................. 5

2.4 Risk factors ..................................................................................................... 6

3 Prevention and early detection ......................................................................... 6

3.1 Prevention ....................................................................................................... 6

3.2 Early detection ............................................................................................... 6

4 Clinical image ..................................................................................................... 6

5 Diagnosis ............................................................................................................ 7

5.1 Diagnostic procedures ................................................................................... 7

5.2 Classification .................................................................................................. 8

5.2.1 Stages .......................................................................................................... 8

5.2.2 Histology .................................................................................................... 10

5.2.2.1 WHO classification ............................................................................... 10

5.2.2.2 TNM/UICC classification ..................................................................... 11

5.2.2.3 Other parameters .................................................................................. 11

6 Therapy ............................................................................................................. 12

6.1 Treatment with curative intention ................................................................. 12

6.1.1 Multidisciplinary approach ....................................................................... 12

6.1.2 Surgery ....................................................................................................... 12

6.1.3 Radiotherapy ............................................................................................. 12

6.1.4 Adjuvant systemic therapy ........................................................................ 14

6.1.5 Induction chemotherapy ............................................................................ 14

6.2 Therapy with non-curative intention .............................................................. 14

6.2.1 First-line treatment ................................................................................... 15

6.2.2 Second-line treatment .............................................................................. 16

6.2.3 Systemic treatment agents (in alphabetical order) ..................................... 17

6.2.3.1 -fluorouracil ......................................................................................... 17

6.2.3.2 Carboplatin .......................................................................................... 17

6.2.3.3 Cetuximab ........................................................................................... 17

6.2.3.4 Cisplatin ............................................................................................... 18

6.2.3.5 Docetaxel ............................................................................................. 18

6.2.3.6 Methotrexate ....................................................................................... 18

6.2.3.7 Mitomycin C ......................................................................................... 18

6.2.3.8 Nivolumab ........................................................................................... 19
Head and neck squamous cell carcinomas

Date of document: October 2022

Compliance rules:
- Guideline
- Conflict of interests

Authors: Konrad Klinghammer, Melanie Boxberg, Peter Brossart, Wilfried Budach, Andreas Dietz, Michael Flentje, Viktor Grünwald, Orlando Guntinas-Lichius, Dennis Hahn, Max Heiland, Korinna Jöhrens, Maren Knödler, Florian Kocher, Sacha Rothschild, Bernhard Wörmann, Georg Maschmeyer

1 Summary

Head and neck carcinomas represent a heterogeneous group of tumors between the skull base and the clavicle with sometimes very different etiologic factors and treatment principles. In this guideline, reference is made exclusively to squamous cell carcinomas arising in the oral cavity, lip, oropharynx, hypopharynx, and larynx, while nasopharyngeal, nasal cavity/paranasal sinus, and salivary gland carcinomas are not addressed. 90% of head and neck carcinomas in the upper aerodigestive tract discussed here are squamous cell carcinomas, and for 75% of these tumors, there is an association with nicotine and alcohol use. Whereas until a few decades ago, all head and neck carcinomas were grouped together, currently, comparable to other oncological diagnoses, there is an increasing diversification driven by different tumor biology and prognosis of the diseases. An example are the HPV-associated carcinomas of the oropharynx, which occur more frequently in younger patients, show less association with nicotine and alcohol, and have a significantly better prognosis than HPV-negative tumors.

In patients with head and neck tumors, a curative treatment approach is pursued in early and in some locally advanced stages. Therapeutic options are surgery, radiation, chemotherapy and immunotherapy, mostly combined as multimodal treatment concepts. Close multidisciplinary cooperation is a prerequisite for the optimal treatment of patients with head and neck tumors. Relevant innovations in recent years are the clearly emphasized transoral resection procedures, such as laser microsurgery (TLM) and robot-assisted surgery (TORS), the one-stage coverage of even complex defects with the help of patient-specific implants, the use of modern tissue-sparing radiation techniques, and the introduction of immunotherapy in the treatment concepts.

2 Basics

2.1 Definition and basic information

Head and neck squamous cell carcinomas (HNSCC) are epithelial malignancies originating primarily in the upper aerodigestive tract. Therapy-oriented guidelines differentiate according to localization, histological, and rarely also genetic and immunohistochemical parameters.

2.2 Epidemiology (Figures 1-4)

Incidence and mortality for HNSCC have not changed significantly since 2000, with a decrease in new cases in men compared to a slight increase in incidence in women, especially for laryngeal cancer, but also for oral cavity and pharyngeal carcinoma, since 2011. According to data from the German Cancer Registry, 12,660 men and 4,560 women developed head and neck cancer in Germany in 2014. In 2015, 5,504 men (43%) and 1,659 women (36%) died from their
tumor disease. HNSCC is the fourth most common tumor in Germany in men at approximately 5%, with an age-standardized mortality of 6.7 per 100,000 population. In women, this rate is lower at 1.8 per 100,000 [1-3].

Due to anti-smoking campaigns, a decrease of the disease is shown in the USA, whereas in Germany this trend is not observed due to a lack of effective programs. Smoking is associated with a worse prognosis in patients with HPV-associated oropharyngeal carcinoma, comparable to HPV-negative carcinomas.

**Figure 1: Incidence and mortality of laryngeal carcinoma in Germany (age-standardized rate)**

![Graph showing incidence and mortality of laryngeal carcinoma in Germany](image)

**Legend:**
Source: Center for Cancer Registry Data (Robert-Koch Institute) as of 31 October 2022

**Figure 2: Laryngeal carcinoma in Germany: numbers of new diagnoses and deaths**

![Graph showing numbers of new diagnoses and deaths](image)

**Legend:**
Source: Center for Cancer Registry Data (Robert-Koch Institute) as of 31 October 2022

The mean age of onset at diagnosis is 63 years for men and 65 years for women, which is 7 years (men) and 4 years (women) below the mean age of onset for cancer overall. The median age at death for the most common location in the oral cavity and pharynx is 66 years (men) and 72 years (women). Most cases of oral cavity and pharyngeal cancer occur in men between 60 and 70 years of age, whereas in women, cases are fairly constant from 55 years of age onward, with a slight peak in those over 85 years of age. The number of new cases per age group depends on the age-specific risk of disease, but also on the age structure of the population. This results in apparent discrepancies between the risk of disease and the number of cases.
2.3 Pathogenesis

Invasive HNSCC develop in the vast majority by two main routes: on the one hand, these tumors arise in connection with tobacco and alcohol consumption and, on the other hand, through infection with human papillomaviruses, in particular HPV-16. Tumors of the head and neck region develop in a complex, stepwise process through the accumulation of genetic alterations. In particular, the inactivation of tumor suppressor genes and the activation of proto-oncogenes play a role, which result in genetic instability. While the carcinogenesis of toxin-associated tumors is a complex process, the tumorigenesis of HPV-associated carcinomas follows a
pattern in which the expression of the viral proteins E6 and E7 leads to the inactivation of p53 and Rb [4].

2.4 Risk factors

The risk of developing HNSCC is increased by the following factors:

- Alcohol consumption [5]
- Smoking [6-8]
- HPV (exclusively in the oropharynx) [9]
- Poor oral hygiene [10]
- Chronic infection [10, 11]
- Chronic mechanical irritation [12]
- Betel nut consumption (oral cavity carcinoma) [13]
- Positive family history for head and neck tumors [14].
- Long-term immunosuppression [15]
- Rare: Fanconi anemia, Li-Fraumeni syndrome, Bloom's syndrome, ataxia telangiectatica, congenital dyskeratosis, lichen ruber planus.

In particular, smoking and regular alcohol consumption are by far the most important risk factors, as they potentiate each other [16].

3 Prevention and early detection

3.1 Prevention

The general recommendations for prevention refer to the previously identified risk factors of smoking and regular alcohol consumption.

3.2 Early detection

Patients with Fanconi anemia are recommended to be enrolled in a regular screening program.

4 Clinical image

Symptoms depend on the localization of the tumor disease. Common to all localizations may be clinical signs such as weight loss, pain, dysphagia, odynophagia, and hemoptysis.

Specific symptoms are summarized in Table 1.

Table 1: Localization-dependent symptoms in patients with head and neck squamous cell carcinoma

<table>
<thead>
<tr>
<th>Cause</th>
<th>Symptom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral cavity</td>
<td>Non-healing ulcers, tooth loosening, dysarthria as a sign of invasion of deep muscle layers, leukoplakia</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>Oropharynx: sleep apnea syndrome, throat swelling, globus sensation</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>Hypopharynx: Otalgia due to the affection of cranial nerves V, VII, IX and X</td>
</tr>
<tr>
<td>Larynx</td>
<td>Hoarseness, stridor</td>
</tr>
</tbody>
</table>
5 Diagnosis

5.1 Diagnostic procedures

In addition to a detailed medical history, a combination of inspection, palpation and mirror examination or flexible laryngoscopy is part of the standard diagnostic procedures. In addition, performance status, nutritional status, psychosocial history, dental status, and assessment of speech and swallowing function should be obtained. In patients over 70 years of age, a geriatric assessment is also recommended. Panendoscopy (endoscopy of the pharyngeal area, trachea and upper bronchi, and esophagus) under anesthesia is an important component of staging procedures for tumors of the larynx and pharynx and is used for histological confirmation, reliable size assessment before definitive therapy, and exclusion of synchronous second malignancies.

CT or MRI of the neck should be performed to exclude metastases and to assess resectability. Especially in advanced tumors, extended diagnostics by CT of the thorax and abdomen are recommended to detect any distant metastases or second malignancies. CT is superior to MRI with regard to the detection of lymph node metastases, whereas MRI is better at imaging perineural tumor invasion, cartilage involvement, and intracranial infiltration. These two techniques should therefore be considered complementary. In cases of suspected lymph node (LN) metastasis and undetectable primary, fine-needle biopsy of the lymph nodes should be sought.

PET-CT is superior to CT for the detection of occult lymphatic metastases. As in general for cross-sectional imaging, but especially for PET-CT, due to false negative findings in metastases < 5 mm, the procedure cannot stratify for or against definitive treatment of lymphatic pathways [17].

Recommendations for diagnosis and staging are summarized in Table 2.

Table 2: Diagnostic procedures for suspected HNSCC and subsequent staging

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical examination</td>
<td>Including an examination of the head and neck</td>
</tr>
<tr>
<td>Laboratory (blood)</td>
<td>Blood counts, liver and kidney function parameters, coagulation, TSH</td>
</tr>
<tr>
<td>Laryngoscopy; ENT; Panendoscopy</td>
<td>For surgical treatment planning and exclusion of other neoplasms; no panendoscopy in oral cavity carcinoma</td>
</tr>
<tr>
<td>Histology</td>
<td>Histopathological findings</td>
</tr>
<tr>
<td>Dental status</td>
<td>Before an examination under anesthesia or surgical tumor therapy, in order to complete repair as early as possible</td>
</tr>
<tr>
<td>Computed tomography neck (or alternatively MRI neck), thorax, abdomen with contrast medium</td>
<td>If indicated, in combination with PET</td>
</tr>
<tr>
<td>Sonography abdomen and neck</td>
<td>If indicated, complementary to computed tomography</td>
</tr>
<tr>
<td>Positron emission tomography - computed tomography (PET-CT)</td>
<td>Exclusion of distant metastases, planning of surgery, planning of radiotherapy</td>
</tr>
<tr>
<td>Bronchoscopy and esophagoscopy</td>
<td>No standard procedure, but indicated in case of specific symptoms or diagnostic findings (e.g., to exclude secondary neoplasms or a tracheobronchial fistula).</td>
</tr>
<tr>
<td>Functional assessment of important organ functions</td>
<td>Clarification of functional operability and assessment of potential therapy-related toxicities before systemic therapy and/or RT.</td>
</tr>
<tr>
<td>Screening for malnutrition</td>
<td></td>
</tr>
</tbody>
</table>
PET-CT may allow to detect occult distant metastases and thus modify the therapeutic procedure in the case of an otherwise resectable primary tumor and, in particular, determine the procedure for surgical removal of neck lymph nodes. In Germany, PET-CT is reimbursed on the basis of a decision by the Joint Federal Committee in the situation where a decision is to be made after primary radiochemotherapy, as to whether neck lymph nodes must be removed [18]. In addition, it is important for the search for occult primary tumors in cervical lymph node metastasis and in follow-up, when it is necessary to differentiate between therapy-induced tissue senescence and tumor recurrence.

5.2 Classification

5.2.1 Stages

The current UICC/TNM classification for lip, oral cavity carcinoma and for p16-negative oropharyngeal carcinoma is depicted in Table 3, and for p16-positive oropharyngeal carcinoma in Table 4.

<table>
<thead>
<tr>
<th>UICC stage</th>
<th>Stage group-&lt;br&gt;ing</th>
<th>Lip, oral cavity and p16 (HPV)-negative oropharynx cancer stage description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Tis N0 M0</td>
<td>The cancer is still within the epithelium (the top layer of cells lining the oral cavity and oropharynx) and has not yet grown into deeper layers. It has not spread to nearby lymph nodes (N0) or distant sites (M0). This stage is also known as carcinoma in situ (Tis).</td>
</tr>
<tr>
<td>I</td>
<td>T1 N0 M0</td>
<td>The cancer is 2 cm or smaller. It is not growing into nearby tissues (T1). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).</td>
</tr>
<tr>
<td>II</td>
<td>T2 N0 M0</td>
<td>The cancer is larger than 2 cm but no larger than 4 cm. It is not growing into nearby tissues (T2). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).</td>
</tr>
<tr>
<td>III</td>
<td>T3 N0 M0</td>
<td>The cancer is larger than 4 cm (T3). For cancers of the oropharynx, T3 also includes tumors that are growing into the epiglottis (the base of the tongue). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).</td>
</tr>
<tr>
<td>OR</td>
<td>T1, T2, T3 N1 M0</td>
<td>The cancer is any size and may have grown into nearby structures if oropharynx cancer (T1-T3) AND has spread to 1 lymph node on the same side as the primary tumor. The cancer has not grown outside of the lymph node and the lymph node is no larger than 3 cm (N1). It has not spread to distant sites (M0).</td>
</tr>
</tbody>
</table>
| IVA        | T4a N0 or N1 M0    | The cancer is any size and is growing into nearby structures such as:  
  - For lip cancers: nearby bone, the inferior alveolar nerve (the nerve to the jawbone), the floor of the mouth, or the skin of the chin or nose (T4a)  
  - For oral cavity cancers: the bones of the jaw or face, deep muscle of the tongue, skin of the face, or the maxillary sinus (T4a)  
  - For oropharyngeal cancers: the larynx (voice box), the tongue muscle, or bones such as the medial pterygoid, the hard palate, or the jaw (T4a).  
  This is known as moderately advanced local disease (T4a). AND either of the following:  
  - It has not spread to nearby lymph nodes (N0)  
  - It has spread to 1 lymph node on the same side as the primary tumor, but has not grown outside of the lymph node and the lymph node is no larger than 3 cm (N1). It has not spread to distant sites (M0). |
| OR         | T1, T2, T3 or T4a N2 M0 | The cancer is any size and may have grown into nearby structures (T0-T4a). It has not spread to distant organs (M0). It has spread to one of the following:  
  - One lymph node on the same side as the primary tumor, but it has not grown outside of the lymph node and the lymph node is larger than 3 cm but not larger than 6 cm (N2a) OR  
  - It has spread to more than 1 lymph node on the same side as the primary tumor, but it has not grown outside any of the lymph nodes and none are larger than 6 cm (N2b) OR  
  - It has spread to 1 or more lymph nodes either on the opposite side of the primary tumor or on both sides of the neck, but has not grown outside any of the lymph nodes and none are larger than 6 cm (N2c). |
| IVB        | Any T N3 M0        | The cancer is any size and may have grown into nearby soft tissues or structures (Any T) AND any of the following:  
  - It has spread to 1 lymph node that is larger than 6 cm but has not grown outside of the lymph node (N3a) OR  
  - It has spread to 1 lymph node that’s larger than 3 cm and has clearly grown outside the lymph node (N3b) OR  
  - It has spread to more than 1 lymph node on the same side, the opposite side, or both sides of the primary cancer with growth outside of the lymph node(s) (N3b) OR  
  - It has spread to 1 lymph node on the opposite side of the primary cancer that is 3 cm or smaller and has grown outside of the lymph node (N3b). It has not spread to distant organs (M0). |
| OR         | T4b Any N M0       | The cancer is any size and is growing into nearby structures such as the base of the skull or other bones nearby, or it surrounds the carotid artery. This is known as very advanced local disease (T4b). It might or might not have spread to nearby lymph nodes (Any N). It has not spread to distant organs (M0). |
| IVC        | Any T N M1         | The cancer is any size and may have grown into nearby soft tissues or structures (Any T) AND it might or might not have spread to nearby lymph nodes (Any N). It has spread to distant sites such as the lungs (M1). |

<table>
<thead>
<tr>
<th>AJCC stage</th>
<th>Stage grouping</th>
<th>p16 (HPV)-positive oropharynx cancer stage description*</th>
</tr>
</thead>
</table>
| I          | T0, T1 or T2 N0 or N1 M0 | The cancer is no larger than 4 cm (T0 to T2) AND any of the following:  
• It has not spread to nearby lymph nodes (N0) OR  
• It has spread to 1 or more lymph nodes on the same side as the primary cancer, and none are larger than 6 cm (N1). It has not spread to distant sites (M0). |
| II         | T0, T1 or T2 N2 M0 | The cancer is no larger than 4 cm (T0 to T2) AND it has spread to 1 or more lymph nodes on the opposite side of the primary cancer or both sides of the neck, and none are larger than 6 cm (N2). It has not spread to distant sites (M0). |

OR

| T3 or T4 N0 or N1 M0 | The cancer is larger than 4 cm (T3) OR is growing into the epiglottis (the base of the tongue) (T3) OR is growing into the larynx (voice box), the tongue muscle, or bones such as the medial pterygoid plate, the hard palate, or the jaw (T4) AND any of the following:  
• It has not spread to nearby lymph nodes (N0) OR  
• It has spread to 1 or more lymph nodes on the same side as the primary cancer, and none are larger than 6 cm (N1). It has not spread to distant sites (M0). |

III        | T3 or T4 N2 M0 | The cancer is larger than 4 cm (T3) OR is growing into the epiglottis (the base of the tongue) (T3) OR is growing into the larynx (voice box), the tongue muscle, or bones such as the medial pterygoid plate, the hard palate, or the jaw (T4) AND it has spread to 1 or more lymph nodes on the opposite side of the primary cancer or both sides of the neck, and none are larger than 6 cm (N2). It has not spread to distant sites (M0). |

IV         | Any T Any N M1 | The cancer is any size and may have grown into nearby structures (Any T) AND it might or might not have spread to nearby lymph nodes (Any N). It has spread to distant sites such as the lungs or bones (M1). |

Legend:

* The following additional categories are not described in the Tables above:

- TX: Main tumor cannot be assessed due to lack of information.
- T0: No evidence of a primary tumor.
- NX: Regional lymph nodes cannot be assessed due to lack of information.

5.2.2 Histology

5.2.2.1 WHO classification

Diagnosis is usually made by biopsy of the primary or an accessible lymph node metastasis.

HNSCCs are evaluated according to the current 4th edition of the WHO classification. The classification defines subtypes with prognostic relevance (verrucous/basaloid/sarcomatoid/"conventional"). The "conventional" carcinomas (keratinizing/non-keratinizing) are graded according to their similarity to regular squamous epithelium (G1/G2/G3), but it should be mentioned that according to the WHO classification the prognostic significance of this grading is very limited. Tumors of the oropharynx have a special role, since HPV testing should be performed for all of them. For this purpose, immunohistochemical staining for p16 is recommended in the WHO classification and is accepted as a surrogate marker for HPV positivity in the oropharynx (includes tonsils and base of tongue). In this context, a tumor at this localization is considered positive, if more than 70% of the tumor cells show nuclear and/or cytoplasmic staining. Other test methods include, for example, PCR testing or RNA detection. It should be noted that HPV-associated HNSCC are not graded. Due to the per se fragmented basement membrane in lymphoepithelial tissue, no precursor lesions (carcinoma in situ) are defined for these carcinomas - they are always rated as invasive.
5.2.2.2 TNM/UICC classification

The pathological workup of resected tissue specimens should include pathological staging according to the current TNM/UICC classification, see also Chapter 5.2.1. This includes the following parameters:

1. Tumor size (pT1-4), with additional specification of depth of invasion for oral HNSCC.
   1. Nodal status for all carcinomas of the head and neck and for the p16-negative oropharyngeal carcinomas (pN1-3), which includes the number of resected and the number of affected lymph nodes and their location. Regarding the lymph nodes, the size of the largest metastasis and an assessment of extracapsular extension (ECE) should be provided.
   2. Nodal status (pN1-pN2) for the p16-negative oropharyngeal carcinomas, where only the number of affected lymph nodes (pN1: up to 4 LN or pN2: 5 or more LN) is taken into account, but not the size or extracapsular infiltration.
4. Perineural sheath infiltration (Pn), lymphangiosis or haemangiosis carcinomatosa (L or V, respectively). These parameters are classified as present or absent.
5. Resection status (R0/R1/Rx): The width of the tumor-free resection margins must also be specified.

These parameters are considered prognostically significant determinants of adjuvant treatment stratification. As mentioned above, this applies to the significance of grading only to a limited extent. It should be noted that the current TNM classification classifies p16-negative and p16-positive HNSCC as separate entities in distinct systems.

5.2.2.3 Other parameters

In addition to these obligatory parameters, a statement regarding the growth pattern of the carcinoma is recommended. The prognostic significance of tumor budding has been proven in many studies, so that it can be assumed that this could be included in the guidelines in the future. Tumor budding can be specified as absent/weak/strong.

A special entity are so-called "cancers of unknown primary (CUP)". These are squamous-cell lymph node metastases in patients with no detectable primary tumor. Here, p16 immunohistochemistry and EBV in situ hybridization are recommended as standard. Positivity may indicate small HPV-associated HNSCC or EBV-associated nasopharyngeal carcinoma as the primary. CUP in which no primary tumor can be found even by these and other ancillary investigations, are addressed in a separate scheme in the current UICC/TNM classification.

In relapsed or metastatic HNSCC, PD-L1 expression status should be determined by immunohistochemistry. In the current regulatory situation in Germany (as of August 2022), the combined positive score (CPS) is used as a predictive biomarker; a score ≥ 1 is classified as positive. A CPS score of ≥ 20 may be particularly relevant for therapy stratification. For this reason, the calculated CPS value should always be reported.
6 Therapy

6.1 Treatment with curative intention

6.1.1 Multidisciplinary approach

In the treatment of locoregionally limited HNSCCs, radiotherapy is a curative adjuvant treatment approach, either alone or in combination with systemic therapy, in addition to surgery. Due to complex treatment options, recommendations should always be discussed and decided on a multidisciplinary basis (multidisciplinary tumor board). In very early tumor stages (T1-2 N0 M0), surgery alone or radiotherapy are available. The treatment decision depends largely on functional aspects and individual patient tolerance. In addition to tumor-specific factors, these patient-specific factors play a special role, since typical HNSCC-associated comorbidities with potential cardiovascular, pulmonary or hepatic limitations are often present, may significantly complicate therapy and can lead to de facto inoperability in tumors despite surgical resectability [19].

6.1.2 Surgery

A first-line surgical approach is recommended for T3/T4 oral cavity carcinomas. Advanced hypopharyngeal carcinomas should upfront be treated surgically, especially in the presence of cartilage invasion. For T3/T4a tumors of the larynx and hypopharynx, the possibility of laryngeal preservation should be discussed in the multidisciplinary tumor board (20). In early T stages and selected cases of advanced T stages, a transoral approach is favored, when technically feasible, because of the lower treatment-associated morbidity. Here, procedures with classical cold instruments, laser surgery, and transoral robotic surgery are used. Depending on the expected tissue defect and functional loss, reconstructive surgery with regional-flap plasty or free-flap plasty is performed. The standard of surgical treatment of the neck soft tissues is neck dissection. The extent and radicality depends on the tumor entity, T and N stage. Salvage surgery may be indicated for tumor progression under/after primary radio(chemo)therapy or for resectable recurrent tumors.

6.1.3 Radiotherapy

Radiotherapy pursues a curative therapeutic approach using at least 60 Gray (Gy); usually $>66$ Gy are given in single doses of 2 Gy. Three-dimensional conformal planning of the irradiation fields is a prerequisite for curative radiation therapy. Procedures such as intensity-modulated radiation therapy (IMRT) or image-guided radiation therapy (IGRT) reduce the morbidity of irradiation, so that these procedures are now routinely used.

In advanced stages III, IVa and IVb, simultaneous radiochemotherapy (RCT) is the therapeutic standard instead of radiotherapy alone. Doses of 70 Gy, 72-76.8 Gy, and 72 Gy, respectively, are used depending on the radiation technique (1 × 2 Gy daily, 2 × 1.2 Gy daily, or “concomitant boost”). This therapeutic approach has been particularly well studied in tumors of the oropharynx and larynx in stages III and IV of non-metastatic disease.

Numerous studies have evaluated the efficacy of cisplatin in combination with radiation. The MACH-NC meta-analysis included individual patient data from 93 randomized trials with a total of 17,346 patients [21]. Chemotherapy was given either as induction therapy, concurrently, or sequentially after locoregional therapy. Simultaneous RCT proved to be the most favorable procedure. In 50 randomized trials of simultaneous RCT involving 9,615 patients, the hazard ratio for mortality decreased to 0.81 ($p < 0.0001$) compared with radiotherapy alone, and the
absolute survival gain at 5 years was 6.5% [21]. In most studies, cisplatin ± 5-fluorouracil (5-FU) was combined with radiotherapy. Here, cisplatin was usually given at a dose of 100 mg/m² body surface area three times during radiotherapy (total dose 300 mg/m²). In the only negative study, cisplatin was obviously underdosed with a total of 20 mg/m² weekly × 7 [21]. In patients over 70 years of age, although the number of patients studied was small, no survival benefit was demonstrated by concurrent chemotherapy in randomized trials. In contrast, large prospective databases show a survival benefit even in >70-year-old patients, if they were in a good general condition (ECOG Performance Score 0-1). Therefore, the indication for concurrent chemotherapy in elderly patients must be discussed very thoroughly [22].

Regarding the choice of the concurrent chemotherapy, no clinically relevant differences were demonstrated between therapy with cisplatin alone or cis- or carboplatin in combination with 5-FU. Therapy without cis-/carboplatin and 5-FU is not recommended. In the presence of contraindications to platinum, mitomycin C +/- 5 FU may be combined with radiotherapy [23, 24]. In contrast to the initial favorable data of the “Bonner study” for oropharyngeal carcinoma [6], current data show inferiority of cetuximab compared with cisplatin therapy [25-27].

Prospective databases and a meta-analysis also show inferiority of cetuximab to cisplatin in HPV-negative tumors [28].

In an evaluation by the MACH-NC group, the benefit of RCT was again confirmed. By including large numbers of patients, the absolute survival gain by RCT compared to radiotherapy alone could also be demonstrated for the individual tumor localizations. After 5 years, the absolute survival gain after RCT was 8.9% for tumors of the oral cavity, 8.1% for oropharyngeal cancer, 5.4% for laryngeal cancer, and 4% for carcinomas of the hypopharynx [29]. When compared to regimens with 3 weekly administration of cisplatin 100mg/m², current data indicate that weekly administration of cisplatin in a dosage of 40mg/m² appears non-inferior but better tolerated. A minimum cumulative dose > 200mg/m², however, seems important in this setting [30, 31].

Due to the better prognosis of HPV-positive oropharyngeal carcinomas, the question of de-intensifying RCT by replacing cisplatin with cetuximab was raised. The NRG-RTOG-1016 phase III trial failed to demonstrate noninferiority of cetuximab. Patients treated with radiotherapy plus cetuximab had a higher rate of locoregional recurrence (17% vs. 10%) and lower 5-year survival (78% vs. 85%) [32, 33].

The use of immune checkpoint inhibitors has been studied in several phase II/III trials in combination with radiation in advanced tumors. As a result of the study results, their use cannot be recommended so far [34-36].

Preoperative radiotherapy alone, in order to improve resectability and eliminate microscopic tumor portions outside the resection margins, has not been successful.

If R0 resection could be performed, adjuvant radiotherapy or radiochemotherapy should be administered for the following indications:

**Indication for adjuvant radiotherapy is based on the presence of risk factors:**

- **pT ≥3**
- **pN2 or pN3 or >1 LN (pN1) with HPV positivity**
- **Perineural invasion (Pn1)**
- **Lymphovascular invasion (V1)**

**Indication for radiochemotherapy:**

- **Extracapsular extension (ECE+)**
• Tumor-free resection margin < 5 mm or R1

Adjuvant treatment should be given within 6 weeks post-resection, provided there are no wound healing problems.

The extent to which the addition of cisplatin chemotherapy in advanced stage III or IV tumors results in prolonged survival is controversial. Weekly administration of cisplatin at 40 mg/m² is noninferior to 3-weekly administration at 100 mg/m² [37]. Postoperative RCT resulted in improved local control compared with radiotherapy alone, as demonstrated in two large independent trials (EORTC 22931; n = 334 and RTOG 9501; n = 459). However, at 10-year follow-up, only the high-risk group of patients with extracapsular extension and positive resection margin showed a persistent significant difference in terms of disease-free survival and local control. For patients with increased risk of recurrence based on T3 and T4 tumors, perineural or vascular invasion, and two or more affected lymph nodes, the addition of chemotherapy to radiotherapy is not unequivocally beneficial because of the nonsignificant differences in disease-free survival and local control.

6.1.4 Adjuvant systemic therapy

According a meta-analysis including a total of about 2,500 patients, adjuvant chemotherapy alone after successful primary therapy (R0 resection) is not indicated, since the 5-year survival rate of 48.4% was not better than that in the control arm with 49.4% [38, 39]. Data on the adjuvant use of checkpoint inhibitors are currently not available.

6.1.5 Induction chemotherapy

Primary chemotherapy of locally advanced but not metastatic HNSCC was shown to be highly effective in historical trials with remission rates of ≥ 80%, but it was not clear whether this approach leads to better long-term outcomes than simultaneous RCT. Through meta-analysis of 31 trials with 5,311 patients, who received locoregional treatment immediately or only after induction chemotherapy (ICT), a marginal increase in 5-year survival from 30% to 32.4% was demonstrated for induction therapy [21]. The comparison between induction and simultaneous radiochemotherapy also indicates a superior effectiveness of simultaneous RCT.

Two meta-analyses evaluating individual data from a combined total of 33 randomized trials with a total of 5,211 patients demonstrated that induction therapy reduced distant metastasis rates by 8% in patients with head and neck cancer, but did not affect local control or overall survival [40, 41]. For laryngeal preservation in very advanced tumors that would require laryngectomy or pharyngectomy, induction chemotherapy followed by radiotherapy alone may be used. Larynx preservation rates are higher using induction followed by radiochemotherapy, but associated with increased toxicity and comparable survival rates [42]. The randomized TAX323 trial evaluated the superiority of a combination of docetaxel, cisplatin, and 5-FU (TPF) for induction chemotherapy over the two-drug combination of cisplatin and 5-FU (PF). The study showed a survival benefit in favor of TPF, albeit with high toxicity [43]. Follow-up after the first cycle by imaging and panendoscopy allows assessment of the likelihood of success of laryngeal preservation, and a tumor size reduction of ≥ 30% should be achieved to justify continuation of induction chemotherapy for a total of 3 cycles [44]. Patients with advanced infiltration of the laryngeal cartilage should be offered a primary surgical approach including laryngectomy. In other localizations of HNSCC beyond the larynx, ICT has not demonstrated a benefit at this time [45]. Currently, studies are investigating the use of PD-1 inhibitors in the neoadjuvant setting.

6.2 Therapy with non-curative intention

An algorithm for first-line therapy in non-curative intention is shown in Figure 5.
6.2.1 First-line treatment

In the presence of distant metastases or locoregionally advanced disease that cannot be controlled by surgery or radiotherapy, palliative systemic therapy should be offered, if the patient is in a good general condition (ECOG PS 0-2). Overall survival with palliative systemic therapy is between 12 and 15 months on median [46-48]. In case of oligometastasis, the option of surgery or radiotherapy in addition to or instead of systemic therapy should be discussed in a multidisciplinary tumor board.

In most cases, partial remission of the tumor is achieved by chemotherapy. Complete remissions are rare. The goal of therapy, in addition to prolonging survival, is to maintain or improve the quality of life.

The standard for first-line palliative therapy has fundamentally changed with the Keynote-048 trial and TPExtreme trial. The Keynote-048 trial randomized the long-standing standard of care of the Extreme protocol with cisplatin, 5-FU, and cetuximab (PF-C) followed by cetuximab maintenance [43] against the immune checkpoint inhibitor pembrolizumab alone or in combination with cisplatin, and 5-FU followed by pembrolizumab maintenance [46]. Pembrolizumab resulted in prolonged overall survival of 14.9 versus 10.7 months in monotherapy, especially in PD-L1 high-expressing tumors (CPS ≥ 20), with a significantly better side effect profile. However, the response rate was lower than with PF-C at 23.3% vs. 36.1%, and more patients were also primarily progressive with pembrolizumab monotherapy than with PF-C. With a CPS ≥ 1, there is also an overall survival benefit of 12.3 months vs. 10.3 months, with 38.9% being primarily progressive in this group. With pembrolizumab, cisplatin, and 5-FU, overall survival is also significantly prolonged compared with PF-C for CPS ≥ 1, with comparable remission rates. However, the rate of adverse events is comparable to Extreme and significantly higher than with pembrolizumab alone.
Regarding chemotherapy in combination with the anti-EGFR antibody cetuximab, a randomized phase II trial compared PF-C with the TPEx protocol (cisplatin, docetaxel, cetuximab), each followed by cetuximab maintenance [47]. Chemotherapy was shortened from 6 cycles to 4 cycles with TPEx, and the total cisplatin dose was reduced by 50% compared with PF-C. Overall survival was comparable with overall lower toxicity and shortened chemotherapy duration with TPEx. The response rate with the docetaxel-containing regimen was also comparable to the control arm at 57%, demonstrating the high efficacy of the regimen. Thus, TPEx can be used as an alternative first-line therapy to PF-C in patients in good general condition, remission pressure, high tumor burden, regardless of PD-L1 status. G-CSF administration was mandatory in the study treatment and is recommended for clinical practice.

6.2.2 Second-line treatment

An algorithm for second-line palliative therapy is shown in Figure 6.

Figure 6: Palliative second-line therapy

For patients with progression after platinum-containing chemotherapy, treatment with the anti-PD-1 immune checkpoint inhibitor nivolumab, compared with a monotherapy using a taxane (paclitaxel or docetaxel), methotrexate (MTX) or cetuximab, significantly prolonged survival to 7.5 versus 5.1 months [49]. Nivolumab is approved for this indication regardless of PD-L1 expression in HNSCC after failure of platinum-based therapy. In a comparable study design, similar results were obtained for the PD-1 inhibitor pembrolizumab, although (pre-specified) statistical significance was achieved only for the patient group with a PD-L1 TPS ≥ 50% [50]. For patients with a PD-L1 TPS ≥ 50%, median overall survival was significantly better at 11.6 months with pembrolizumab versus 6.6 months with a taxane, MTX, or cetuximab, resulting in an approval for patients with TPS ≥ 50% after failure platinum-based prior therapy.

In light of these study results, in the absence of contraindications to a checkpoint inhibitor in second-line therapy after P-FC or TPEx, treatment should be with nivolumab (regardless of PD-L1 expression) or pembrolizumab (TPS ≥ 50%).
After first-line therapy with pembrolizumab mono or PF-pembrolizumab, there is no standard therapy established by study results. A retrospective analysis showed a high remission rate of 30% by salvage chemotherapy after checkpoint inhibition with a median overall survival of 7.6 months after a median of 2 prior therapies [51]. Thus, increased chemotherapy sensitivity after checkpoint inhibition can be hypothesized, however, no established sequential therapy approach has been established to date.

6.2.3 Systemic treatment agents (in alphabetical order)

6.2.3.1 -fluorouracil

5-FU is used for systemic therapy of patients with head and neck cancers in the (neo-)adjuvant and metastatic setting. In contrast to therapy with 5-FU in other tumor entities, there is no indication that a combination with folinic acid will increase efficacy. Oral fluoropyrimidines such as capecitabine have no proven therapeutic relevance in HNSCCs. Serious adverse effects include diarrhea and stomatitis. Patients with functionally relevant polymorphisms of 5-FU degradation genes are at an increased risk for severe side effects including neutropenia and neutropenic fever. It is mandatory since 04/2020 to test all patients for dihydropyrimidine dehydrogenase (DPD) deficiency (either by measuring the level of uracil or by testing for the presence of specific polymorphisms) before starting treatment with 5-FU, according to the recommendations of the European Medicines Agency (EMA), and to implement appropriate therapeutic consequences depending on the results.

6.2.3.2 Carboplatin

Carboplatin can be used as an alternative in case of contraindications to cisplatin, especially with regards to nephrotoxicity. It has not yet been randomized against cisplatin, and cisplatin is standard in combination with radiotherapy and in palliative systemic therapy. For fit patients ≥70 years of age (geriatric assessment recommended), combination of carboplatin, 5-FU, and cetuximab showed a PFS of 7.2 mo. and an OS of 14.7 mo., so for fit elderly patients, when platinum, 5-FU plus cetuximab are used, the administration of carboplatin can be considered [52].

6.2.3.3 Cetuximab

Cetuximab competes with ligands for the binding site at the EGF receptor. If cetuximab binds, there is no phosphorylation of the tyrosine kinase and activation of the signaling cascade. In addition, internalization of the receptor and subsequent degradation occurs, resulting in a decrease in EGFR expression. A third mechanism, antibody dependent cellular cytotoxicity (ADCC), leads to the immigration of NK and cytotoxic T cells, resulting in lysis of antibody-bearing cells. A further antiproliferative effect is achieved by reduced release of angiogenic growth factors. The antibody was initially investigated in the "BONNER study" in combination with radiotherapy in a curative setting. Radiochemotherapy showed significantly longer progression-free (24.4 vs. 14.9 months) and overall survival (49 vs. 29.3 months) compared with radiotherapy alone [53]. In the subsequent RTOG 0522 trial, cetuximab in combination with cisplatin and radiotherapy was compared with cisplatin radiotherapy alone. No benefit was obtained here for the addition of cetuximab in any of the relevant endpoints [54]. The EXTREME trial evaluated cetuximab in combination with chemotherapy in the palliative setting. The combination of platinum, 5-FU, and cetuximab resulted in significantly longer survival, becoming the new standard of care in the palliative setting [48]. Cetuximab was thus the first and, until 2017, the only approved targeted therapy in the treatment of HNSCC.
6.2.3.4 Cisplatin

Cisplatin is the treatment standard in combination with radiotherapy for locally advanced disease and is used in combination therapy in the palliative setting. In definitive radiochemotherapy, cisplatin is given as monotherapy and should reach a total dose of $\geq 200$ mg/m$^2$. Weekly administration of 40 mg/m$^2$ showed non-inferiority in overall survival and a better side effect profile than administration of 100 mg/m$^2$ every 3 weeks in a phase II/III study [55]. Fractionated administration of weekly cisplatin also showed noninferiority in the adjuvant setting [37]. The extent to which the previous standard of 100 mg/m$^2$ is superseded by these data in the definitive as well as the adjuvant setting is currently a matter of controversy. In palliative therapy, cisplatin is combined with 5-FU and pembrolizumab or with cetuximab plus 5-FU or docetaxel, achieving remission rates between 36% and 59% with a median overall survival of 13-14 months. Specific severe adverse effects (grade 3/4) include nausea and vomiting, nephrotoxicity, polyneuropathy, ototoxicity, hematotoxicity, electrolyte shifts, cardiotoxicity, and diarrhea.

6.2.3.5 Docetaxel

Docetaxel as a monotherapeutic agent, along with platinum derivatives, is one of the agents with the highest activity in HNSCC. As a monotherapy, studies have evaluated doses of 40 mg/m$^2$ weekly or 100 mg/m$^2$ every 3 weeks in patients with head and neck tumors. Objective response rates ranged from 27% to 32% in pretreated patients [56-58]. In the TPEx trial, docetaxel was combined with cisplatin and cetuximab. Based on the efficacy data and favorable toxicity profile, compared with cisplatin, 5 FU, and cetuximab (Extreme protocol), the docetaxel combination is considered the therapeutic standard in the first-line palliative treatment of fit patients whose HNSCC lack PD-L1 expression [47]. Furthermore, the compound is effective as monotherapy in second-line therapy or in combination with the EGFR antibody cetuximab. Severe adverse effects (grade 3/4) include infection, nail dystrophy, taste disturbance, stomatitis, and diarrhea. Burdensome adverse effects (grade 2) include alopecia. Particularly distressing is polyneuropathy, which may be irreversible. Common side effects such as nausea/vomiting and allergic reactions can be prevented by adequate supportive therapy.

6.2.3.6 Methotrexate

Methotrexate can be used as monotherapy, when platinum-based chemotherapy is contraindicated, and results in a remission rate of 3.9% with a median overall survival of 6.7 months compared with gefitinib (40 mg/m$^2$ weekly) in a randomized phase III trial of [59]. Side effects with MTX were predominantly mucositis, nausea, and constipation.

6.2.3.7 Mitomycin C

Mitomycin belongs to the group of alkylating antibiotics with antiproliferative activity. In the ARO 95-06 trial, mitomycin was administered together with 5-FU and hyperfractionated radiation compared with radiation therapy alone. After a median follow-up of 8.7 years, local tumor control was 12% higher than the control rate for radiotherapy alone. Mitomycin C/5-FU can thus be used concomitantly to radiation therapy as an alternative to cis- or carboplatin in the presence of contraindications [23].
6.2.3.8 Nivolumab

Nivolumab is a checkpoint inhibitor that binds to PD-1 and has been evaluated in previously treated HNSCC. The Checkmate-141 phase III study evaluated nivolumab against "investigator's choice" (methotrexate, docetaxel, or cetuximab) in 361 platinum-refractory patients. Overall survival with nivolumab was 7.7 months vs. 5.1 months, and there was a 1-year survival rate of 34% vs. 19.7% in the control arm. The response rate (ORR) was 13.3% vs. 5.8%. In an exploratory preplanned analysis, overall survival was shown to be dependent on PD-L1 expression ≥ 1 (8.7 vs. 4.6 months). The survival benefit could not be demonstrated in patients whose HNSCC did not express PD-L1 [49]. Quality-of-life studies showed that no worsening occurred with nivolumab compared with the control arm [60]. Based on the study results, nivolumab was approved in Europe for platinum-pretreated HNSCC patients.

6.2.3.9 Paclitaxel/nab-paclitaxel

Paclitaxel, like docetaxel, is one of the active agents in HNSCC. Paclitaxel has been studied in combination with platinum and cetuximab in first-line palliative and second-line setting. The CSPOR-HN02 and CETMET trials investigated the role of paclitaxel in first-line palliative therapy. Both trials included only a small number of patients. Effectiveness was comparable to that of other combinations with 5-FU or docetaxel in combination with platinum derivatives. In the advanced tumor setting, Hitt et al. studied a well-tolerated regimen of paclitaxel 80 mg/m² weekly in combination with cetuximab in 46 patients, demonstrating an ORR of 54%, a PFS of 4.2 months and an OS of 8.1 months.

For cremophor-free albumin-linked nab-paclitaxel, only one small phase II trial (CACTUX) is available to date, which showed a high ORR of 63%, a PFS of 6.8 months and an OS of 18.8 months.

6.2.3.10 Pembrolizumab

Pembrolizumab is an immune checkpoint inhibitor binding to PD-1, which was evaluated for first-line palliative therapy in the Keynote-048 trial and in advanced disease in Keynote-040. In Keynote-048 (882 patients, phase III), the combination of pembrolizumab with cisplatin and 5-FU was compared to the standard of care cisplatin, 5-FU and cetuximab (PFC; EXTREME regimen). Furthermore, the comparison of pembrolizumab as monotherapy versus PFC was performed. Comparison of the two arms with checkpoint inhibitor was not performed in the 3-arm study. PD-L1 expression was determined by CPS.

The study demonstrated prolonged overall survival compared with the control arm with chemotherapy (median 13.0 vs. 10.7 months, 2-year survival 29% vs. 19%, HR 0.77, 95% CI 0.63-0.93). The effect of immunotherapy added to chemotherapy was particularly evident in the PD-L1 positive population: CPS ≥20 (median overall survival 14.7 vs. 11.0 months, 2-year survival 35% vs. 19%, HR 0.60; 95% CI 0.45-0.82) and CPS ≥1 (median 13.6 vs. 10.4 months, 2-year survival 31% vs. 17%, HR 0.65, 95% CI 0.53-0.80).

Pembrolizumab monotherapy compared with the chemotherapy combination PFC showed superior overall survival, but lower response (17% vs. 36%) and poorer progression-free survival (2.3 months vs. 5.2 months, HR 1.34; 95% CI 1.13-1.59) - in subgroups with CPS ≥20 (PFS median 14.9 vs. 10.7 months, 2-year survival 38% vs. 22%, HR 0.61; 95% CI 0.45-0.83) and with CPS ≥1 (PFS median 12.3 vs. 10.3 months, 2-year survival 30% vs. 19%, HR 0.78; 95% CI 0.64-0.96)
Data from the Keynote-048 trial led to the approval of pembrolizumab with or without chemotherapy for first-line treatment in patients with CPS ≥1.

Pembrolizumab was previously evaluated in a patient population with platinum-refractory head and neck tumors in comparison to "investigator's choice" (cetuximab, docetaxel, or methotrexate) in the Keynote-040 trial. Pembrolizumab prolonged survival (1-year survival 37 vs. 27%, median overall survival 8.4 vs. 6.9 months, HR 0.80; 95% CI 0.65-0.98). The survival benefit was particularly strong in patients with PD-L1 high-expressing tumors (HR 0.53; 95% CI 0.35-0.81), as determined by TPS. Based on these data, pembrolizumab was approved for pretreated patients with a PD-L1 TPS ≥50% [46, 50].

6.3 Special situations

6.3.1 Bone metastases

Bone metastases occur with a frequency between 2% and 22% depending on the primary tumor location and may lead to bone fractures, spinal cord compression or hypercalcemia in 27%. Hypercalcemia, due to the secretion of parathyroid related petide (PTHrP) frequently observed in squamous cell carcinoma, is the most common complication. Patients with bone metastases have a very unfavorable median survival of only 6 months, with the use of radiotherapy and bisphosphonates favorably affecting survival. Therefore, it is recommended to start antiresorptive therapy when bone metastases are detected and to combine it with radiotherapy in symptomatic patients [62].

7 Rehabilitation

Head and neck tumors by themselves, but also their treatment by means of surgery, systemic anticancer therapy and/or radiotherapy, often lead to considerable stress, a loss of quality of life, and functional and somatic sequelae such as post-therapeutic chewing, speaking and swallowing disorders or radiation-induced xerostomia, weight loss up to tumor cachexia, chemotherapy-induced polyneuropathy and general weakness up to a (chronic) fatigue syndrome. As a result of these side effects, corresponding comorbidities (e.g., alcohol abuse) and the oncological diagnosis itself, there is a high psychological burden and corresponding need for psychosocial and psychosocial care. Therefore, targeted rehabilitation measures are necessary. These should take place as soon as possible after completion of the primary therapy. During rehabilitation, in addition to the general therapy offers (sports/physio-/ergo therapy), comprehensive nutritional counseling and nutritional support should be provided, patients should be included in a teaching kitchen, and there should be the possibility of administering all scientifically recognized forms of nutrition - from normal whole food, enteral nutrition to complete parenteral nutrition. In Germany, the costs of dental rehabilitation with dental implants after therapy of HNSCC are mostly covered by the insurance companies (§28 SGB V). Rehabilitation facilities should be able to continue medical tumor therapies, if indicated. Patients who have not yet reached the statutory retirement age should be informed about services for participation in working life within the framework of medical-occupational oriented rehabilitation (MBOR). Further socio-medical questions as well as any other required patient care should be clarified during rehabilitation. Furthermore, every patient should be offered psycho-oncological care.

8 Follow-up

After curative treatment, structured follow-up is required to detect early recurrences or second malignancies and to detect long-term toxicities. The majority of recurrences occur within the first two years after primary therapy. Clinical follow-up is scheduled every 3 months during years 1 and 2, and every 6 months in years 3 to 5. For locally advanced tumors, cross-sectional
imaging to check for local recurrence and to eventually detect second tumors is recommended: CT or MRI at 6-month intervals during the first two years and then every 12 months until the fifth year. PET-CT is (still) reserved for special questions and patients after curative RCT in order to decide on neck dissection in case of positive lymph nodes. In addition, cross-sectional imaging should be considered in case of clinical complaints or abnormal clinical examination findings [63].

9 References


41. Budach W, Bolke E, Kammers K et al. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of


10 Authors’ Affiliations

**PD Dr. med. Konrad Klinghammer**  
Charité Universitätsmedizin Berlin  
Medizinische Klinik mit Schwerpunkt Hämatologie,  
Onkologie und Tumorimmunologie (CBF)  
Hindenburgdamm 30  
12203 Berlin  
konrad.klinghammer@charite.de
PD Dr. med. Melanie Boxberg
Technische Universität München
Institut für Pathologie
Trogerstr. 18
81675 München
melanie.boxberg@tum.de

Prof. Dr. med. Peter Brossart
Universitätsklinikum Bonn
Medizinische Klinik III
Onkologie und Hämatologie
Sigmund-Freud-Str. 25
53105 Bonn
peter.brossart@ukb.uni-bonn.de

Prof. Dr. med. Wilfried Budach
Universitätsklinikum Düsseldorf
Klinik für Strahlentherapie und Radioonkologie
Moorenstrasse 5
40225 Düsseldorf
wilfried.budach@med.uni-duesseldorf.de

Prof. Dr. med. Andreas Dietz
Universitätsklinikum Leipzig
Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde
Liebigstrasse 10-14
04103 Leipzig
andreas.dietz@medizin.uni-leipzig.de

Prof. Dr. med. Michael Flentje
Universitätsklinikum Würzburg
Klinik und Poliklinik für Strahlentherapie
Josef-Schneider-Str. 11
97080 Würzburg
flentje_m@ukw.de

Prof. Dr. med. Viktor Grünwald
Universitätsklinikum Essen
Innere Klinik
Tumorforschung
Hufelandstr. 55
45147 Essen
Viktor.Gruenwald@uk-essen.de

Prof. Dr. med. Orlando Guntinas-Lichius
Universitätsklinikum Jena
Klinik für Hals-, Nasen- und Ohrenheilkunde
Kastanienstr. 1
07747 Jena
orlando.Guntinas@med.uni-jena.de
Dr. Dennis Hahn
Katharinenhospital Stuttgart
Klinik für Hämatologie und Onkologie
Kriegsbergstr. 60
70174 Stuttgart
d.hahn@klinikum-stuttgart.de

Prof. Dr. Dr. med. Max Heiland
Charité Universitätsmedizin Berlin
Klinik für Mund-, Kiefer- und Gesichtschirurgie
Augustenburger Platz 1
13353 Berlin
max.heiland@charite.de

Prof. Dr. Korinna Jöhrens
Universitätsklinikum Carl Gustav Carus
Institut für Pathologie
Fetscherstr. 74
01307 Dresden
Korinna.Joehrens@uniklinikum-dresden.de

Dr. med. Maren Knödler
Charité Universitätsmedizin Berlin
Campus Mitte
Charité Centrum für Multidisziplinäre Medizin
Charitéplatz 1
10117 Berlin
maren.knoedler@charite.de

Dr. med. Florian Kocher
Medizinische Universität Innsbruck
Universitätsklinik für Innere Medizin V
Anichstr. 35
A-6020 Innsbruck
florian.kocher@i-med.ac.at

Prof. Dr. med. Dr. phil. Sacha Rothschild
Zentrum Onkologie / Hämatologie
Kantonsspital Baden AG
Im Ergel 1
CH-5404 Baden
Sacha.Rothschild@ksb.ch

Prof. Dr. med. Bernhard Wörmann
Amb. Gesundheitszentrum der Charité
Campus Virchow-Klinikum
Med. Klinik m.S. Hämatologie & Onkologie
Augustenburger Platz 1
13344 Berlin
bernhard.woermann@charite.de
Disclosures

according to the rules of DGHO, OeGHO, SGH+SSH, SGMO
<table>
<thead>
<tr>
<th>Author</th>
<th>Employer1</th>
<th>Consulting / Expert opinion2</th>
<th>Shares / Funds3</th>
<th>Patent / Copyright / License 4</th>
<th>Fees5</th>
<th>Funding of scientific research6</th>
<th>Other financial relations7</th>
<th>Personal relationship with authorized representatives8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boxberg, Melanie</td>
<td>Pathologie München Nord Ernst-Platz Str. 2 80992 München Institut für Pathologie der TU München Trogerstr. 18 81675 München</td>
<td>Yes Advisoryboards von BMS/MSD</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Drittmittel von BMS</td>
<td>No</td>
</tr>
<tr>
<td>Brossart, Peter</td>
<td>Universitätssklinikum Bonn</td>
<td>Yes BMS, AMGEN, AstraZeneca</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>BMS</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Budach, Wilfried</td>
<td>Universitätssklinikum Düsseldorf</td>
<td>Yes Advisory Board: MSD, Merck, Pfizer, BMS</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No med publico GmbH; MSD; Merck; Jörg Eickeler Beratung, Düsseldorf; Deutsche Akademie für Senologie</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Dietz, Andreas</td>
<td>Universitätssklinikum Leipzig</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Vortragshonorare MSD, Sanofi, Sun,</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Flentje, Michael</td>
<td>Klinikum der Universität Würzburg</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Grünwald, Viktor</td>
<td>Uniklinik Essen</td>
<td>Yes Apogepha BMS Cureteq Debiopharm EISAI EUSA Pharm Merck Serono MSD Oncorena PCI Biotech Pfizer Pfizer Roche</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Guntinas-Lichius, Orlando</td>
<td>Universitätssklinikum Jena</td>
<td>Yes Advisory Merz Pharma Novartis MEDICE</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Hahn, Dennis</td>
<td>Klinikum Stuttgart Klinik für Hämatologie, internist. Onkologie, Palliativmedizin und Stammzelltransplantation</td>
<td>Yes BMS, Merck, MSD, Takeda</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>BMS, Merck, MSD, Takeda</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Author</td>
<td>Employer</td>
<td>Consulting / Expert opinion</td>
<td>Shares / Funds</td>
<td>Patent / Copyright / License</td>
<td>Fees</td>
<td>Funding of scientific research</td>
<td>Other financial relations</td>
<td>Personal relationship with authorized representatives</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------------------------</td>
<td>-----------------------------</td>
<td>----------------</td>
<td>-------------------------------</td>
<td>------</td>
<td>-------------------------------</td>
<td>--------------------------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>Heiland, Max</td>
<td>Charité Universitätsmedizin Berlin Klinik für Mund-, Kiefer- und Gesichtschirurgie</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td></td>
<td>Research grants/ contracts (restricted or unrestricted) KLS Martin From: 01.03.2022 To: 09.06.2022 Translation Oberflächen-modifizierter Implantat-Systeme Forschungs-förderung 1.370.000 institutionell Research grants/contracts (restricted or unrestricted) AO Foundation From: 01.01.2019 To: 13.06.2022 MRONJ Registry Vergütung pro eingeschlossenem Patienten 5.000 institutionell Research grants/contracts (restricted or unrestricted) DFG via Universitätssklinikum Heidelberg From: 01.01.2019 To: 13.06.2022 APOS Studie, nein Vergütung pro eingeschlossenem Patienten 3.500 institutionell</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Type of interest</td>
<td>Cooperation partner/source of funding</td>
<td>Period of cooperation/activity</td>
<td>Thematic scope of the project, reference to the guideline</td>
<td>Type of the grant</td>
<td>Value of the grant</td>
<td>Recipient</td>
<td>Other financial relations</td>
<td>Personal relationship with authorized representatives</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------------</td>
<td>------------------------------</td>
<td>----------------------------------------------------------</td>
<td>------------------</td>
<td>-------------------</td>
<td>------------</td>
<td>---------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>Consulting / Expert opinion</td>
<td>Consultant MKG Honorar</td>
<td>From: 01.01.2019 To: 09.06.2022</td>
<td></td>
<td>Consultant MKG Honorar</td>
<td>198,000</td>
<td></td>
<td></td>
<td>Tätigkeit als Berater<em>in bzw. Gutachter</em>in oder bezahlte Mitarbeit in einem wissenschaftlichen Beirat / Advisory Board eines Unternehmens der Gesundheitswirtschaft (z. B. Arzneimittelindustrie, Medizinproduktindustrie), eines kommerziell orientierten Auftragsinstituts oder einer Versicherung type of interest</td>
</tr>
<tr>
<td>Shares / Funds</td>
<td>Foundation</td>
<td>From: 01.07.2021 To: 09.06.2022</td>
<td>Mitglied im AOCMF International Board</td>
<td></td>
<td>17,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patent / Copyright / License</td>
<td>Advisory boards AO</td>
<td>From: 02.04.2019 To: 02.04.2019</td>
<td>Expert Meeting, Advanced Squamous Cell Carcinoma</td>
<td>Honorary 400</td>
<td></td>
<td></td>
<td></td>
<td>Tätigkeit als Berater<em>in bzw. Gutachter</em>in oder bezahlte Mitarbeit in einem wissenschaftlichen Beirat / Advisory Board eines Unternehmens der Gesundheitswirtschaft (z. B. Arzneimittelindustrie, Medizinproduktindustrie), eines kommerziell orientierten Auftragsinstituts oder einer Versicherung type of interest</td>
</tr>
<tr>
<td>Fees</td>
<td>Nanobiotix</td>
<td>From: 06.11.2021 To: 06.11.2021</td>
<td>Expertenmeeting Kopf-Hals-Tumor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author</td>
<td>Employer1</td>
<td>Consulting / Expert opinion2</td>
<td>Shares / Funds3</td>
<td>Patent / Copyright / License 4</td>
<td>Fees5</td>
<td>Funding of scientific research6</td>
<td>Other financial relations7</td>
<td>Personal relationship with authorized representatives8</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------</td>
<td>------------------------------</td>
<td>-----------------</td>
<td>--------------------------------</td>
<td>-------</td>
<td>-------------------------------</td>
<td>--------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Jöhrens, Korinna</td>
<td>Carl Gustav Carus Universitätsklinikum Dresden, Institut für Pathologie</td>
<td>Yes MSD, Agilent, EUSA, QuIP</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>MSD, Agilent, BMS, EUSA, QuIP, Targos, AstraZeneca</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Klinghammer, Konrad</td>
<td>Charité Universitätsmedizin Berlin</td>
<td>Yes -MSD -Merck -BMS -Bayer</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>-MSD -Merck -BMS</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Knödler, Maren</td>
<td>Aktuell: Charité Universitätsmedizin Berlin CCCC, CCM Bis 8/22 Universitätssklinikum Leipzig, Universitäres Krebszentrum, Med. Klinik</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Kocher, Florian</td>
<td>Medizinische Universität Innsbruck</td>
<td>Yes MSD, Merck</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>MSD, Merck</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Maschmeyer, Georg</td>
<td>Charité Universitätsmedizin Berlin; DGHO (freiberuflich); bis 31.3.2022: Klinikum Ernst von Bergmann Potsdam</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Gilead Sciences GmbH (Vorträge und Veranstaltungsmoderation Infektionen); Merck-Serono (Moderation Roundtable Kolorektale Karzinome), Bristol-Myers Squibb (Vortrag Thema Immuntherapie von Tumorerkrankungen), AMGEN (Vortrag Thema Infektionen), AstraZeneca (Moderation Thema Immuntherapie von Tumorerkrankungen); Janssen-Cilag (Vortrag Infektionen); medupdate GmbH (Vortrag Neuigkeiten Hämatologie); RG (Vortrag/Moderation Highlights Hämatologie/Onkologie); FOMF GmbH (Kopf-Hals-Tumoren)</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Author</td>
<td>Employer1</td>
<td>Consulting / Expert opinion2</td>
<td>Shares / Funds3</td>
<td>Patent / Copyright / License4</td>
<td>Fees5</td>
<td>Funding of scientific research6</td>
<td>Other financial relations7</td>
<td>Personal relationship with authorized representatives8</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------</td>
<td>------------------------------</td>
<td>-----------------</td>
<td>-------------------------------</td>
<td>-------</td>
<td>-------------------------------</td>
<td>---------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Rothschild, Sacha</td>
<td>ab 11/2022 Kantonsspital Baden, Zentrum für Onkologie &amp; Hämatologie 07/2011-10/2022 Universitätsspital Basel, Medizinische Onkologie</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Amgen, Astellas, Astra-Zeneca, Bayer, BMS, Boehringer-Ingeheim, Eisai, Eli Lilly, Janssen, Merck Serono, MSD, Novartis, Otsuka, Pfizer, PharmaMar, Roche Pharma, Roche Diagnostics, Sanofi, Takeda (Bezahlungen an die Institution)</td>
<td>Yes</td>
</tr>
<tr>
<td>Wörmann, Bernhard</td>
<td>DGHO, Charité Universitätsmedizin Berlin</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Legend:

1. - Current employer, relevant previous employers in the last 3 years (institution/location).
2. - Activity as a consultant or expert or paid participation in a scientific advisory board of a company in the health care industry (e.g., pharmaceutical industry, medical device industry), a commercially oriented contract research organization, or an insurance company.
3. - Ownership of business shares, stocks, funds with participation of companies of the health care industry.
4. - Relates to drugs and medical devices.
5. - Honoraria for lecturing and training activities or paid authors or co-authors on behalf of a company in the health care industry, a commercially oriented contracting institute or an insurance company.
6. - Financial support (third-party funds) for research projects or direct financing of employees of the institution by a company in the health care industry, a commercially oriented contract institute or an insurance company.
7. - Other financial relationships, e.g., gifts, travel reimbursements, or other payments in excess of 100 euros outside of research projects, if paid by an entity that has an investment in, license to, or other commercial interest in the subject matter of the investigation.
8. - Personal relationship with an authorized representative(s) of a healthcare company.